These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23537510)

  • 21. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Ghosh S; Rowin J; Meriggioli MN; Christadoss P
    Neuromuscul Disord; 2006 Feb; 16(2):137-43. PubMed ID: 16427283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
    Kaminski HJ; Li Z; Richmonds C; Lin F; Medof ME
    Exp Neurol; 2004 Oct; 189(2):333-42. PubMed ID: 15380483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells and cytokines in the pathogenesis of acquired myasthenia gravis.
    Milani M; Ostlie N; Wang W; Conti-Fine BM
    Ann N Y Acad Sci; 2003 Sep; 998():284-307. PubMed ID: 14592887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased expression of miR-29 family associated with autoimmune myasthenia gravis.
    Cron MA; Payet CA; Fayet OM; Maillard S; Truffault F; Fadel E; Guihaire J; Berrih-Aknin S; Liston A; Le Panse R
    J Neuroinflammation; 2020 Oct; 17(1):294. PubMed ID: 33032631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
    Tüzün E; Saini SS; Morgan BP; Christadoss P
    J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Age-related resistance to experimental autoimmune myasthenia gravis in rats.
    Graus YM; Verschuuren JJ; Spaans F; Jennekens F; van Breda Vriesman PJ; De Baets MH
    J Immunol; 1993 May; 150(9):4093-103. PubMed ID: 8386206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
    Fuchs S; Aricha R; Reuveni D; Souroujon MC
    J Autoimmun; 2014 Nov; 54():51-9. PubMed ID: 24970384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis.
    Losen M; Stassen MH; Martínez-Martínez P; Machiels BM; Duimel H; Frederik P; Veldman H; Wokke JH; Spaans F; Vincent A; De Baets MH
    Brain; 2005 Oct; 128(Pt 10):2327-37. PubMed ID: 16150851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Animal models of myasthenia gravis.
    Christadoss P; Poussin M; Deng C
    Clin Immunol; 2000 Feb; 94(2):75-87. PubMed ID: 10637092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introducing Autoimmunity at the Synapse by a Novel Animal Model of Experimental Autoimmune Myasthenia Gravis.
    Wang J; Xiao Y; Zhang K; Luo B; Shen C
    Neuroscience; 2018 Mar; 374():264-270. PubMed ID: 29421431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis.
    Soltys J; Halperin JA; Xuebin Q
    J Neuroimmunol; 2012 Mar; 244(1-2):63-9. PubMed ID: 22325826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complement C2 siRNA mediated therapy of myasthenia gravis in mice.
    Huda R; Tüzün E; Christadoss P
    J Autoimmun; 2013 May; 42():94-104. PubMed ID: 23410585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis.
    Mori S; Kubo S; Akiyoshi T; Yamada S; Miyazaki T; Hotta H; Desaki J; Kishi M; Konishi T; Nishino Y; Miyazawa A; Maruyama N; Shigemoto K
    Am J Pathol; 2012 Feb; 180(2):798-810. PubMed ID: 22142810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis.
    Lennon VA; Seybold ME; Lindstrom JM; Cochrane C; Ulevitch R
    J Exp Med; 1978 Apr; 147(4):973-83. PubMed ID: 206648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis.
    Qi H; Tüzün E; Allman W; Saini SS; Penabad ZR; Pierangeli S; Christadoss P
    J Neuroimmunol; 2008 May; 196(1-2):101-6. PubMed ID: 18455242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.
    Deng C; Goluszko E; Tüzün E; Yang H; Christadoss P
    J Immunol; 2002 Jul; 169(2):1077-83. PubMed ID: 12097416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.
    Stascheit F; Chuquisana O; Keller CW; Ambrose PA; Hoffmann S; Gross CC; Lehnerer S; Wiendl H; Willcox N; Meisel A; Lünemann JD
    Eur J Neurol; 2023 May; 30(5):1409-1416. PubMed ID: 36752022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental autoimmune myasthenia gravis in the mouse.
    Wu B; Goluszko E; Huda R; Tüzün E; Christadoss P
    Curr Protoc Immunol; 2011 Nov; Chapter 15():Unit 15.23. PubMed ID: 22048803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction.
    Gomez AM; Van Den Broeck J; Vrolix K; Janssen SP; Lemmens MA; Van Der Esch E; Duimel H; Frederik P; Molenaar PC; Martínez-Martínez P; De Baets MH; Losen M
    Autoimmunity; 2010 Aug; 43(5-6):353-70. PubMed ID: 20380584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats.
    Chamberlain-Banoub J; Neal JW; Mizuno M; Harris CL; Morgan BP
    Clin Exp Immunol; 2006 Nov; 146(2):278-86. PubMed ID: 17034580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.